Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Caribou Biosciences, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
5.79
12.4
9.6
13.9
34.5
9.99
11.2
Research and development
23.6
34.4
52.3
82.2
112
130
109
General and administrative
16.5
14.1
24.3
38
38.5
46.5
37.9
Operating expenses
40.1
48.5
76.6
120
151
177
160
Operating income
-34.3
-36.1
-67
-106
-116
-167
-148
Interest expense
0
0.02
0.01
Interest income
1.05
0.24
0.15
Other non-operating income
3.34
-0
0.38
7.05
14.2
17.5
-0.33
Pre-tax income
-31
-36.1
-66.6
-99.4
-102
-149
-149
Income tax
-7.54
-1.82
0.32
0.07
0.19
-0.01
-0.55
Net income
-23.4
-34.3
-66.9
-99.4
-102
-149
-148
EBITDA
-33.6
-35.2
-66
-105
-113
-163
-145
EPS, basic
-2.80
-4.01
-2.11
-1.64
-1.38
-1.65
-1.59
EPS, diluted
-2.80
-4.01
-2.11
-1.64
-1.38
-1.65
-1.59
Shares, basic (weighted)
8.37
8.55
31.7
60.8
73.8
90.3
93.4
Shares, diluted (weighted)
8.37
8.55
31.7
60.8
73.8
90.3
93.4
Balance sheet
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
41.1
16
240
58.3
51.2
16.3
12.4
Short-term investments
0
135
189
278
193
127
Receivables
0.15
1.15
0.2
0.15
0.27
0.07
Other current assets
3.19
7.24
7.92
6.16
6.59
2.91
Total current assets
24.3
391
260
339
219
145
Property, plant and equipment
3.5
4.89
10.7
18.3
19.3
6.76
Lease right-of-use assets
0
24.2
22.2
20
17.7
Long-term investments
0
37.7
69.4
43.6
39.8
3.51
Other non-current assets
0.61
0.98
1.54
1.59
5.52
2.2
Total assets
36
442
374
432
313
175
Accounts payable
2.6
3.99
1.15
3.12
2.48
5.78
Accrued liabilities
8.97
13.1
16.1
21.1
23.6
16.5
Deferred revenue
0.05
8.7
9.94
2.85
3.13
1.9
Total current liabilities
12.4
25.8
28.1
28.3
30.7
25.4
Lease liabilities
0
26.8
25.9
25.1
26
Total liabilities
18.2
54.5
72.9
63.8
60.4
53.2
Paid-in capital
7.43
486
500
668
701
719
Retained earnings
-30.9
-97.8
-197
-299
-448
-597
Other comprehensive income
0
-0.14
-1.52
0.03
0.26
0.1
Shareholders' equity
7.46
-23.4
388
301
368
253
122
Total equity
7.46
-23.4
388
301
368
253
122
Total liabilities and equity
36
442
374
432
313
175
Shares outstanding
9.71
60.3
61
88.4
92.4
95.1
Cash flow statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-23.4
-34.3
-66.9
-99.4
-102
-149
-148
Depreciation and amortization
0.75
0.9
0.98
1.62
3.53
3.93
3.65
Stock-based compensation
1.23
1
3.45
11.7
13.8
16.7
12.7
Deferred income tax
-7.11
-0.92
0.32
-0.1
0.18
-0.01
-0.55
Change in receivables
0.62
-0.15
-1
0.95
0.05
-0.12
0.2
Change in payables
1.18
0.04
1.14
-2.72
1.82
-0.35
3.25
Cash from operations
-32
-33.2
-32.5
-91
-93.3
-138
-111
Capital expenditures
-0.88
-0.32
-2.12
-6.45
-11.6
-4.88
-1.36
Purchases of investments
0
0
-173
-339
-395
-304
-149
Sales and maturities of investments
0
253
Cash from investing
27.2
6.36
-176
-93.2
-68.2
86.6
102
Stock issued
0.22
0.27
2.55
0
1.01
15.2
4.07
Cash from financing
0.17
1.74
433
2.13
154
16.7
4.82
Net change in cash
-4.6
-25.1
225
-182
-7.18
-34.9
-3.93
Free cash flow
-32.9
-33.5
-34.6
-97.4
-105
-143
-112
Income taxes paid
1.81
0.02
0.01
0
0.17
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.24 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-1,091.0%
Operating income / revenue.
EBITDA margin
-1,065.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-1,030.0%
Net income / revenue.
FCF margin
-954.2%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-954.5%
Cash from operations / revenue.
Return on equity (ROE)
-105.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-72.4%
Net income / average total assets.
Return on invested capital (ROIC)
-120.3%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
854.7%
Research and development expense / revenue.
Stock-based pay / revenue
104.7%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.3%
Capital expenditures / revenue.
D&A / revenue
25.8%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
11.7%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-7.0%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-2.0%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-51.7%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-25.9%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-44.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-22.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
37.2%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
3.4%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
15.4%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
61.3%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
6.49x
Current assets / current liabilities.
Quick ratio
6.26x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
6.25x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.10
Revenue / diluted weighted shares.
FCF per share
-$0.95
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.95
Cash from operations / diluted weighted shares.
Book value per share
$0.93
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
13.2x
Market cap / revenue.
P/B
1.36x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.36x
Market cap / tangible book value, when positive.
EV/Sales
2.06x
Enterprise value / revenue.
FCF yield
-72.0%
Free cash flow / market cap.
Earnings yield
-77.8%
Net income / market cap (the inverse of P/E).
What was Caribou Biosciences, Inc.'s revenue in fiscal 2025?
Caribou Biosciences, Inc. reported revenue of $11.2M for fiscal 2025, 11.7% higher than the year before.
Was Caribou Biosciences, Inc. profitable in fiscal 2025?
No. It reported a net loss of $148.1M.
How much free cash flow did Caribou Biosciences, Inc. generate in fiscal 2025?
Cash from operations of $111.0M minus capital expenditures of $1.4M left free cash flow of -$112.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.